Chinese Hepatolgy ›› 2021, Vol. 26 ›› Issue (5): 534-537.

• Liver Cancer • Previous Articles     Next Articles

Effect of sequential treatment of human albumin on liver function and prognosis in patients with primary liver cancer complicated with cirrhosis after radiofrequency ablation

JI Xiao-mei1, SHAO Chun-yan1, JI Hao-ming1, GHAO Chun-yan2   

  1. 1. Department of Oncology, Haian Hospital Affiliated to Nantong University, Jiangsu 226600,China;
    2. Department of Oncology, the Third People's Hospital of Nantong, Jiangsu,226001,China
  • Received:2020-03-13 Online:2021-05-31 Published:2021-06-17
  • Contact: JI Xiao-mei, Email:1052893743@qq.com

PDF (PC)

422

Abstract: Objective To investigate the effect of sequential treatment of human albumin (ALB) in patients with primary liver cancer (PLC) complicated with cirrhosis after ultrasound-guided radiofrequency ablation (RFA).Methods One hundred and ten PLC patients with cirrhosis treated with RFA were selected and divided into 2 groups. After RFA, the observation group was given 5% human ALB and 25% human ALB, while the control group was given 5% human ALB. Data such as liver function and treatment efficacy of the 2 groups were recorded.Results ALB, gamma-glutamyl transferase or total bilirubin had no significant difference between the 2 groups on the day 1 or day 3 after the operation (P>0.05), and they were lower in the observation group than control group on the day 7 (P<0.05). Prealbumin and ration of albumin and globulin were lower in the observation group than the control group (P<0.05) on the day 1 after the treatment, and had no significant difference on day 3 or day 7 (P>0.05). The glomerular filtration rate in the observation group was higher than the control group on day 1 and day 3 (P<0.05), and had no difference between the 2 groups on day 7 (P>0.05). High-sensitivity C-reactive protein was higher in the observation group than the control group on day 1 (P<0.05), and had no significant difference between the 2 groups on day 3 or day 7 (P>0.05). There was no significant difference in prothrombin time or fibrinogen between the 2 groups after treatment (P>0.05). The dosage of ALB and plasma and the time of hospitalization in the observation group were lower than those in the control group (P<0.05). There was no significant difference in complication rate or 1-year survival rate between the 2 groups (P>0.05).Conclusion The sequential treatment of isosmotic and hyperosmotic human ALB in PLC patients with cirrhosis after RFA can effectively improve hypoproteinemia and low blood volume, maintain internal environment stability, promote postoperative recovery and improve the utilization efficiency of ALB.

Key words: Primary liver cancer, Liver cirrhosis, Radiofrequency ablation, Albumin, Sequential treatment